NAME: Wang, Shaoxiang

POSITION TITLE: Associate research fellow; School of Pharmaceutical Sciences, Shenzhen University Health Science Center

EDUCATION/TRAINING

A.   Personal Statement

My primary areas of research are on the basic research and clinical development of molecular-targeted therap ies for esophageal squamous cell carcinoma (ESCC). ESCC has a high incidence, high mortality rate and limited treatment options in China. Advanced research in developed countries has mainly focused on esophageal adenocarcinoma, meaning that ESCC remains poorly understood. My research is, therefore, searching for improved clinical chemotherapy strategies for ESCC. I have applied for 6 patents in this field (as the inventor).

I have published 27 SCI papers, including 14 papers as the first author and corresponding author. I have accumulated extensive experience in the research of the novel cancer target Hsp90 and endoplasmic reticulum stress. I have successfully established many models of esophageal cancer and other cancer types, including a chemically induced model, a nude mouse model, a drug-resistant model, a cancer stem cells sphere model, a MACS model, a side population cell model, and lentivirus stable knockdown models. These models have laid the foundation for future research.

As a project leader, I have presided over seven research projects funded by the National Natural Science Foundation of China, the China Postdoctoral Science Special Foundation, the China Postdoctoral Science Foundation, the Guangdong Natural Science Foundation, and the Shenzhen Science and Technology Project, and have participated in a further six projects including a National 863 Project and a National Natural Foundation Project.

B.   Positions and Employment

10 /201 4 – present       Instructor , Shenzhen University Health Science Center Department of Pharmacy, Shenzhen, China

C.   Contributions to Science (*: corresponding/co-corresponding author ; ^#: first author )

[1]   K.S. Liu^#, H. Liu, J.H. Qi, Q.Y. Liu, Z. Liu, M. Xia, G.W. Xing, S.X. Wang^*, Y.F. Wang^*, SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells. Cancer letters 318 (2012) 180-188.

[2]   S.X. Wang^#, Z. Du^#, J. Luo, X. Wang, H. Li, Y. Liu, Y. Zhang, J. Ma, W. Xiao, Y. Wang^*, X. Zhong^*, Inhibition of heat shock protein 90 suppresses squamous carcinogenic progression in a mouse model of esophageal cancer. Journal of cancer research and clinical oncology (2015) Aug;141(8):1405-16. (IF:3.5024, First author)

[3]   Y. Zhang, Y.L. Wen, J.W. Ma, J.C. Ye, X. Wang, J.X. Huang, C.Y. Meng, X.Z. Xu, S.X. Wang^*, X.Y. Zhong, Tetrandrine inhibits glioma stem-like cells by repressing beta-catenin expression. International journal of oncology 50 (2017) 101-110.

[4]   Y.T. Liu^#, X. Wang^#, Y. Wang, Y. Zhang, K. Zheng, H.Z. Yan, L. Zhang, W.B. Chen, X.Y. Wang, Q.Y. Liu, S.X. Wang^*, Y.F. Wang^*, Combination of SNX-2112 with 5-FU exhibits antagonistic effect in esophageal cancer cells. International journal of oncology 46 (2015) 299-307.

[5]   Y. Zhang^#, S.X. Wang^#, J.W. Ma, H.Y. Li, J.C. Ye, S.M. Xie, B. Du^*, X.Y. Zhong^*, EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition. Journal of neuro-oncology 121 (2015) 41-52.

[6]   H.Q. Ju^#, S.X. Wang^#, Y.F. Xiang, Z. Liu, J.Y. Liu, Z.P. Chen, F.L. Zeng, M. Xia, Z.H. Liu, G.W. Xing, S.Y. Wang, Y.F. Wang^*, BJ-B11, a novel Hsp90 inhibitor, induces apoptosis in human chronic myeloid leukemia K562 cells through the mitochondria-dependent pathway. European journal of pharmacology 666 (2011) 26-34.

[7]   X. Wang^#, S.X. Wang^#, Y.T. Liu, D. Huang, K. Zheng, Y. Zhang, X.Y. Wang, Q.Y. Liu, D.P. Yang^*, Y.F. Wang^*, Comparative effects of SNX-7081 and SNX-2112 on cell cycle, apoptosis and Hsp90 client proteins in human cancer cells. Oncology Reports 33 (2015) 230-238.

[8]   X. Zhou^#, S.X.Wang. ^#, H. Sun, B.J. Wu, Sulfonation of raloxifene in HEK293 cells overexpressing SULT1A3: Involvement of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in excretion of sulfate metabolites. Drug Metab Pharmacokinet 30 (2015):  425-433.

[9]   S.Q. Wang^#, X. Wang^#, K. Zheng, K. S. Liu, S.X. Wang*, C.H. Xie. Simultaneous targeting PI3K and PERK pathways may obtain better treatment and improve the clinical prognosis in esophageal squamous carcinoma. Biochemical and Biophysical Research Communications 493 (2017): 534-541 .

[10]S.X. Wang^#, X. Wang^#, Z. Du, Y.T. Liu, D.N. Huang, K. Zheng, K.S. Liu, Y. Zhang, X.Y. Zhong^*, Y.F. Wang^*, SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG. Biochemical and Biophysical Research Communications 450 (2014) 73-80.

[11]X. Wang^#, S.X. Wang^#, Y.T. Liu, W.C. Ding, K. Zheng, Y.F. Xiang, K.S. Liu, D.M. Wang, Y.Y. Zeng, M. Xia, D.P. Yang^*, Y.F. Wang^*, The Hsp90 inhibitor SNX-2112 induces apoptosis of human hepatocellular carcinoma cells: The role of ER stress. Biochemical and Biophysical Research Communications 446 (2014) 160-166.

[12]H.Y. Li^#, W.W. Xiao^#, J.W. Ma, Y. Zhang, R. Li, J.C. Ye, X. Wang, X.Y. Zhong^*, S.X. Wang^*, Dual high expression of STAT3 and cyclinD1 is associated with poor prognosis after curative resection of esophageal squamous cell carcinoma. International journal of clinical and experimental pathology 7 (2014) 7989-7998.

[13]R. Li^#, H.Y. Li^#, S.X. Wang^#, J.W. Ma, Y. Zhang, J.C. Ye, Y.L. Wen, X. Wang, X.Y. Zhong, W.W. Xiao. Novel prognostic value of nuclear lactate dehydrogenase-A in esophageal squamous cell carcinoma. 2016;9(3):3708-3716, International journal of clinical and experimental pathology (1936-2625).

[14]S.X. Wang^#, H.Q. Ju^#, K.S. Liu, J.X. Zhang, X. Wang, Y.F. Xiang, R. Wang, J.Y. Liu, Q.Y. Liu, M. Xia, G.W. Xing, Z. Liu^*, Y.F. Wang^*, SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells. Bioscience, Biotechnology, and Biochemistry 75 (2011) 1540-1545.

D.   Research Support

Ongoing Research Support

1. Guangdong province science and technology plan project (2017A010105013)     01/01/2017 to 31/12/2018

Shaoxiang Wang, PI                                                                                              ￥400,000

The effect and mechanism of IRE1 inhibition enhancing the drug sensitivity in esophageal cancer stem cells

2. Shenzhen science and technology project (JCYJ20170302145059926)         01/06/2017 to 31/05/2019

Shaoxiang Wang, PI                                                                                              ￥400,000

The effect and mechanism of PERK/eIF2α pathway regulating the drug sensitivity in esophageal cancer cells

Completed Research Support

1. NSFC (China) Youth Fund (81201727)                   01/01/2013 to 12/31/2015

Shaoxiang Wang, PI                                                    ￥230,000

The role of endoplasmic reticulum stress in SNX-2112-induced cell death of esophageal cancer

2. China Postdoctoral Science Special Foundation (2013T60827)               01/10/2013 to 30/09/2015

Shaoxiang Wang, PI                                                                                              ￥150,000

Endoplasmic reticulum stress inhibitor enhances the SNX-2112 effect  in esophageal cancer

3. China Postdoctoral Science Foundation (2012M511882)           01/01/2012 to 31/12/2013

Shaoxiang Wang, PI                                                                                ￥50,000

The role of endoplasmic reticulum stress in SNX-2112-induced cell death of esophageal cancer

4. Guangdong Natural Science Foundation (S2012040006873)     01/10/2012 to 30/09/2014

Shaoxiang Wang, PI                                                                                ￥50,000

The role of endoplasmic reticulum stress inhibition by SNX-2112 in the cell death of esophageal cancer

5. Shenzhen science and technology project (JCYJ20150324141711568)         01/06/2015 to 31/08/2017

Shaoxiang Wang, PI                                                                                              ￥300,000

The effect and mechanism of ERS pathway regulating the drug sensitivity in esophageal cancer stem cells